The Cancer Index · Feb 2026
A company profile focused on Cleancard’s at-home urine-based cancer detection platform and its screening use case.
Making cancer detection as easy as a pregnancy test
Company research
Public company, workplace, funding, and market signals
Overview
Cleancard (rebranded publicly as Numen) is a San Francisco-based biotechnology startup developing rapid at-home cancer screening tests. Its core product is a 30-minute urine-based diagnostic platform that combines synthetic biology, machine learning, and computer vision to detect multiple cancer biomarkers, starting with prostate, bladder, and ovarian cancers.
Primary product
Rapid at-home cancer screening tests from urine samples, delivered through a synthetic-biology + AI diagnostic platform.
Founded
2021
Headquarters
San Francisco, California, United States
Team size
11-50
Industry
Biotechnology
Sub-industry
At-home cancer diagnostics / cancer screening
Offices
350 Parnassus Ave, Suite 300, San Francisco, CA 94117
Westbourne Studios, 242 Acklam Road, London, United Kingdom
Business model
At-home diagnostic test sales
Biotech R&D platform development
Clinical validation / research partnerships
Funding
Stage
Early-stage / accelerator-backed
Total raised
$846K
Latest round
Accelerator/Incubator · Oct 2025
People & investors
Leadership
Chief Executive Officer & Co-Founder
Chief Scientific Officer & Co-Founder
Product & Design Lead
Work & culture
Mission-driven and research-heavy, with a tight-knit team of scientists, engineers, and designers focused on non-invasive cancer diagnostics and rapid product iteration.
Compensation
Public job postings show roughly $90K-$220K base pay depending on role, plus equity ranges around 0.05%-0.25%; at least one role is listed as US citizen/visa only.
Benefits
Competitive salary and benefits package
Professional growth and development
Mission-driven work in healthcare
Collaborative, cross-disciplinary team environment
Product & market
Differentiators
- —30-minute results from a urine sample
- —No expensive machinery required
- —Combines synthetic biology, ML, and computer vision
- —Aims to be faster and cheaper than lab-based tests
- —Multiple biomarker detection from one sample
- —Home-use format for screening outside the clinic
Technology
Synthetic biology
Machine learning
Computer vision
Urine biomarker detection
Multiplexed diagnostics
Aptamer/SELEX-related biosensing
Customers
Patients/consumers seeking at-home cancer screening
Clinical partners involved in validation and follow-up
Competitors
Galleri (GRAIL/Illumina)
Exact Sciences
EarlySign
Traditional lab-based cancer screening tests
Lateral flow rapid diagnostic tests
Scale & contact
Estimated revenue
≈$1.1M estimated annual revenue (2024 estimate)
Latest news
Persana AI Blog · Sep 2025
A profile article describing the company’s founder-led strategy, at-home cancer diagnostics mission, and estimated revenue/funding details.
LinkedIn · Jul 2025
Thomas Carroll announced that Cleancard signed a 9,070 SF lease at 350 Parnassus Avenue near UCSF, signaling continued buildout in San Francisco.
The New Money · Sep 2023
Early coverage of Cleancard’s at-home cancer screening concept, including its use of synthetic biology and computation.
Y Combinator · Aug 2023
Launch announcement describing the company’s product, founders, and initial cancer targets.
Jobs and careers at Cleancard
0 jobs at Cleancard
No open positions
Check back later for new openings